For informational purposes only — not investment advice

← Back to signals

SHC

Sotera Health Co

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
7.5d↑+11.5%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Negative

Sotera Health beat adjusted EPS estimates but missed revenue guidance slightly, with the stock falling 6.7% post-earnings due to weakening European medical device demand and flat Q4 revenue guidance despite maintained full-year outlook. Multiple analyst downgrades (JPMorgan to Underweight, Wall Street Zen from Strong Buy to Buy) reflect growing caution about end-market headwinds, though consensus remains Moderate Buy.

Red flags

  • •Softening European medical device demand noted in mid-to-late Q3 and persisting into early Q4
  • •Guidance for flat sequential revenue in Q4 suggests demand deceleration
  • •Nordion segment revenue declined 12.4% due to Cobalt-60 shipment timing uncertainties
  • •JPMorgan downgrade to Underweight citing heightened uncertainty in medtech end-market
  • •Sharp 6.7% stock sell-off post-earnings despite EPS beat indicates market skepticism about forward guidance
  • •Wall Street Zen downgrade from Strong Buy to Buy reflects reduced conviction

Fund 13D/13G Filings (2)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Sachem Head CapitalSC 13G/A−15.6M0.0%
-2.2% vs SPY
-10.2% abs
2026-10-09↗
Sachem Head CapitalSC 13GNEW5.5%
+19.1% vs SPY
+24.6% abs
2026-05-15↗